Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40382295.
- Also identified by DOI 10.1016/j.eururo.2025.04.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent European Medicines Agency marketing authorisation for belzutifan offers patients with renal cell carcinoma a well-tolerated and effective option for third- and fourth-line treatment. Future studies will assess its efficacy in earlier disease stages.
Medical subject headings
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Antineoplastic Agents